Duska LR, Lim J, Calderon Boyle TA, Guinter M, et al. The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings? Cancer 2025;131:e35821.
PMID: 40351123